

State of Oklahoma SoonerCare

Tagrisso® (Osimertinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	on
Pharmacy billing (NDC:) Start Date (or date of next dose):	
Dose:	Dosing Regimen:	
Billing Provider Information		
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria Cri		
 i. Will osimertinib ii. Is disease epide mutation positive B. Is diagnosis metas i. Is disease EGFF ii. Is disease EGFF C. Will osimertinib be 	ermal growth factor receptor (EGe? Yes No tatic NSCLC? Yes No R T790M mutation-positive? Yes R exon 19 deletion or exon 21 L used as a single agent? Yes	lowing tumor resection? Yes No GFR) exon 19 deletion or exon 21 L858R s No 858R mutation positive? Yes No No gnosis:
3. Has the member experience of yes, please specify adverse in the specific adverse in the specific adverse in the specific and the specific adverse in the specific adverse i	dence of progressive disease we ded adverse drug reactions relate reactions:	
Additional information:		
	atment is medically necessary	Date: y and all information is true and correct to ll will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 79 5/23/2023